# Open-label, Multiple-dose, Phase III Study of the Population Pharmacokinetics of I.V. Synercid in 75 Pediatric Patients

> **NCT00240747** · PHASE3 · TERMINATED · sponsor: **Pfizer**

## Conditions studied

- Gram-Positive Bacterial Infections

## Interventions

- **DRUG:** Synercid

## Key facts

- **NCT ID:** NCT00240747
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2000-06
- **Primary completion:** —
- **Final completion:** 2005-01
- **Target enrollment:** — (—)
- **Last updated:** 2012-05-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00240747

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00240747, "Open-label, Multiple-dose, Phase III Study of the Population Pharmacokinetics of I.V. Synercid in 75 Pediatric Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00240747. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*